Ascelia Pharma AB (publ) (ACE) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.635 Welcome to Acellia Pharma Q3 2025 report presentation. 00:00:04.635 -- 00:00:08.739 For the first part of the conference, participants will be in listen-only mode. 00:00:08.739 -- 00:00:13.184 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.184 -- 00:00:18.629 pound key 5 on their telephone keypad. Now I will hand the conference over to CEO 00:00:18.629 -- 00:00:23.974 Magnus Corfitzen, CSO Andreas Norlin, and Deputy CEO Julie Warris 00:00:23.974 -- 00:00:27.316 Brogren. Please go ahead. 00:00:29.258 -- 00:00:36.044 Hi, everyone, and welcome to the webcast for Celia Fama Q3 Financial Report 2025. 00:00:36.768 -- 00:00:40.911 On this call, we will be making forward-looking statements. 00:00:41.254 -- 00:00:46.280 On today's call, we will start with recent key events and then head into our portfolio 00:00:46.280 -- 00:00:50.526 update before moving to financials and priorities ahead. 00:00:50.526 -- 00:00:55.350 After the presentation, we will open up for questions as usual. 00:00:56.663 -- 00:01:01.829 At Acelia Pharma, we identify, develop, and commercialize novel drugs that address 00:01:01.829 -- 00:01:05.493 unmet medical needs within rare cancer conditions. 00:01:05.493 -- 00:01:09.735 We're based in Malmö, Sweden, and are listed on nasdaq.com. 00:01:10.078 -- 00:01:15.403 We have two drugs in our pipeline. Orbic Lans is in the registration phase as we have 00:01:15.403 -- 00:01:20.569 successfully completed the pivotal phase three clinical study, SPICLE, and have submitted 00:01:20.569 -- 00:01:27.274 the new drug application to the FDA. The FDA is currently reviewing the application. 00:01:27.393 -- 00:01:32.061 OrbeGlance has orphan drug designation from the FDA and is tar...